TSC22D3 Antibody

What is TSC22D3 and why is it significant in research?

TSC22D3 (TSC22 Domain Family Member 3) is a leucine zipper protein functioning as a transcriptional regulator. In humans, the canonical protein has 134 amino acid residues with a mass of 14.8 kDa, localizing in both nucleus and cytoplasm . Its significance stems from:

• Role in anti-inflammatory and immunosuppressive pathways

• Function as a glucocorticoid-responsive gene

• Potential as a prognostic biomarker, particularly in AML

• Involvement in multiple signaling pathways including NF-κB

TSC22D3 is also known by several synonyms: DSIPI, GILZ (Glucocorticoid-Induced Leucine Zipper), TSC-22R, DIP, and others . The protein is reported to be expressed in brain, lung, spleen, and skeletal muscle, with expression strongly induced by glucocorticoids and IL-10 .

What research applications are TSC22D3 antibodies validated for?

TSC22D3 antibodies have been validated for multiple research applications, as summarized in the table below:

How should researchers validate TSC22D3 antibodies before experimental use?

Methodological validation should include:

• Western blot validation: Verify single band at expected molecular weight (~14.8 kDa for canonical form, but note potential isoforms)

• Positive control tissues/cells: Brain, lung, spleen, and skeletal muscle express detectable levels of TSC22D3

• Induction validation: Treatment with dexamethasone (55 μg/100g body weight) significantly increases TSC22D3 expression (3-4 hours before sample collection)

• Knockout/knockdown controls: Verify antibody specificity using TSC22D3 knockdown samples as done in AML cell studies

• Cross-reactivity testing: Important especially when working with orthologs in mouse, rat, bovine, or other species

• Epitope mapping: Different antibodies target distinct regions (AA 1-137, AA 1-97, AA 58-134, etc.), affecting detection of specific isoforms

What factors should guide TSC22D3 antibody selection for specific experiments?

Selection criteria should be based on:

• Target species reactivity: Confirm antibody reactivity with your species of interest (human, mouse, rat)

• Isoform specificity: TSC22D3 has up to 3 reported isoforms; select antibodies targeting relevant domains

• Application compatibility: Verify validation for your specific application (WB, IHC, IF, etc.)

• Epitope location: Antibodies targeting different regions (N-terminal vs C-terminal) may give different results

• Host species considerations: Choose based on compatibility with other antibodies in multi-color experiments

• Clonality: Monoclonal antibodies offer higher specificity; polyclonal antibodies may provide stronger signals

How can TSC22D3 antibodies be optimized for studying its role in immune regulation?

When investigating TSC22D3's immunoregulatory functions, consider these methodological approaches:

• Induction protocols: TSC22D3 expression is strongly induced by:

  • Glucocorticoids (e.g., dexamethasone treatment)

  • IL-10 treatment

• Inhibition experiments: Type 1 interferon (IFN-α) suppresses TSC22D3 expression and reduces GR binding at regulatory regions

• Cell-specific analysis: TSC22D3 has differential effects across immune cell populations:

  • Positive correlation with macrophages, Th1 cells, and Th17 cells

  • Negative correlation with T helper cells and mast cells

• Pathway analysis: Focus on known interaction pathways:

  • NF-κB/NLRP3 signaling (TSC22D3 inhibits this pathway)

  • IL-1β release regulation

  • Macrophage polarization (inhibits M1 subtype)

• Checkpoint molecule co-analysis: TSC22D3 expression significantly correlates with:

  • PD-1 expression (positive correlation)

  • CTLA-4 expression (positive correlation)

What are the latest findings on TSC22D3's role in AML and how can antibodies support this research?

Recent research identifies TSC22D3 as an immune-related prognostic biomarker in AML with significant methodological implications:

Research findings demonstrate that TSC22D3-deficient AML cells show reduced proliferation rate and tumor invasion in mouse cell-derived xenograft (CDX) models, suggesting therapeutic potential in targeting this pathway .

How can researchers optimize ChIP protocols with TSC22D3 antibodies?

For studying TSC22D3's role in transcriptional regulation, optimize ChIP experiments with these methodological considerations:

• Binding site identification: Recent research identified multiple overlapping binding sites for STAT1 and GR in TSC22D3 locus:

  • Promoter region (for TSC22D3 isoform 1)

  • Enhancer region approximately 15kb downstream of the gene

• Protocol optimization:

  • Use L363 human B cell line as a model system

  • Perform dexamethasone treatment to induce GR binding

  • Include IFN treatment conditions to study interference effects

• Target regions:

  • Region A and Z: Located around the promoter of TSC22D3 isoform 1

  • Regions K and L: Located in the enhancer region (show greater sensitivity to IFN interference)

• Controls:

  • Include GR ChIP as positive control

  • Monitor STAT1 binding as a potential competitor

  • Use IgG control for background normalization

What methodological approaches help troubleshoot inconsistent TSC22D3 antibody results?

When facing inconsistent results, implement these systematic troubleshooting steps:

• Isoform verification: Confirm which of the 3 reported isoforms your antibody detects:

  • Canonical isoform: 14.8 kDa

  • Check epitope specificity (e.g., AA 1-137, AA 1-97)

• Expression induction:

  • Glucocorticoid treatment increases TSC22D3 expression (positive control)

  • Type 1 interferon treatment decreases expression (negative control)

• Signal interference assessment:

  • IFN reduces GR binding at TSC22D3 regulatory regions

  • Jak1/Tyk2 inhibitor tosylate salt (TS) can block this interference

• Technical optimization:

  • For weak signals: Extend primary antibody incubation (overnight at 4°C)

  • For high background: Increase blocking stringency (5% milk/BSA)

  • For western blot: Use 12% SDS-PAGE for better resolution of low MW proteins

How should researchers design experiments to study TSC22D3 knockout/knockdown effects?

Based on published methodologies, design your gene manipulation studies with these considerations:

• Knockout model creation:

  • Use Cre/loxP technology targeting exons 3-6 of TSC22D3

  • Include neomycin resistance gene cassette flanked by frt sites

  • Verify knockout via Western blot with anti-TSC22D3 antibody

• Knockdown approach:

  • Use shTSC22D3 vector transfection (validated in Hel cells)

  • Verify knockdown efficiency by:

    • RT-qPCR for mRNA levels

    • Western blot for protein expression

• Functional assessment:

  • Cell proliferation assays

  • Drug sensitivity tests (e.g., cytarabine)

  • Cytokine release measurements (particularly IL-1β)

  • Flow cytometry for immune cell polarization

• In vivo validation:

  • Mouse cell-derived xenograft (CDX) model

  • Single-cell suspensions from tumor tissues for flow cytometry analysis

• Controls:

  • Use pLKD vector as control for shRNA experiments

  • Include both treated and untreated conditions

What buffer systems and protocols optimize TSC22D3 antibody performance?

Based on published methodologies, the following buffer systems enhance antibody performance:

• Western blot protocols:

  • Lysis buffer: 8M urea for tissue lysis using TissueLyser

  • Blocking: Tris-buffered saline with 0.1% Tween and 4% milk powder

  • Resolution: 12% SDS-PAGE gels provide optimal separation

  • Loading control: GAPDH antibody after stripping

• Immunohistochemistry:

  • Fixation: Formalin-fixed paraffin-embedded or frozen sections

  • Antigen retrieval: Citrate buffer (pH 6.0) heat-induced retrieval

  • Blocking: 5% serum from host species of secondary antibody

• Immunofluorescence:

  • Nuclear counterstain: DAPI for nuclear staining

  • Visualization: TSC22D3 shows both nuclear and cytoplasmic localization

• Flow cytometry:

  • Single-cell suspensions preparation from tissue samples

  • FcR blocking: 50% antimouse FcR (CD16/32; clone 2.4.G.2) culture supernatant

  • Co-staining markers based on cell type of interest

How can researchers quantitatively assess TSC22D3 expression levels?

For accurate quantification of TSC22D3, employ these methodological approaches:

• Western blot densitometry:

  • Normalize to housekeeping proteins (GAPDH, β-actin)

  • Use recombinant TSC22D3 as standard curve

• RT-qPCR:

  • Recommended primers target conserved regions

  • Normalize to 18s rRNA using the ∆∆Ct method

  • Include glucocorticoid-treated samples as positive controls

• ELISA quantification:

  • Sandwich ELISA using matched antibody pairs

  • Detection sensitivity range: 0.1-100 ng/ml

  • Capture antibody: rabbit MaxPab® affinity purified polyclonal

  • Detection antibody: mouse purified polyclonal

• Flow cytometry:

  • Mean fluorescence intensity measurement

  • Inclusion of calibration beads for standardization

  • Parallel isotype controls for background subtraction

What experimental controls are essential when working with TSC22D3 antibodies?

Implement these critical experimental controls:

• Positive controls:

  • Tissues: Brain, lung, spleen, skeletal muscle samples

  • Cell lines: U937, MV-4-11, Hel, and THP1 (high mRNA expression)

  • KG-1, MV-4-11, U937, and Hel (high protein expression)

  • Dexamethasone-treated samples (55 μg/100g body weight, 3-4h before collection)

• Negative controls:

  • TSC22D3 knockout/knockdown samples

  • Secondary antibody-only controls

  • Isotype control antibodies

  • Peptide competition assays

• Technical controls:

  • Loading controls for western blot (GAPDH, β-actin)

  • Nuclear/cytoplasmic markers for localization studies

  • Cross-reactivity testing with related proteins (other TSC22D family members)